Memphasys Ltd
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid in vitro antioxidant assessment; and AI-Port… Read more
Memphasys Ltd (MEM) - Total Assets
Latest total assets as of December 2025: AU$10.45 Million AUD
Based on the latest financial reports, Memphasys Ltd (MEM) holds total assets worth AU$10.45 Million AUD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Memphasys Ltd - Total Assets Trend (2007–2025)
This chart illustrates how Memphasys Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Memphasys Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Memphasys Ltd's total assets of AU$10.45 Million consist of 12.1% current assets and 87.9% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 2.7% |
| Accounts Receivable | AU$900.94K | 8.2% |
| Inventory | AU$58.82K | 0.5% |
| Property, Plant & Equipment | AU$567.43K | 5.2% |
| Intangible Assets | AU$9.11 Million | 82.6% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2007–2025)
This chart illustrates how Memphasys Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Memphasys Ltd's current assets represent 12.1% of total assets in 2025, an increase from 0.0% in 2007.
- Cash Position: Cash and equivalents constituted 2.7% of total assets in 2025, down from 4.7% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 82.0% of total assets, an increase from 0.0% in 2007.
- Asset Diversification: The largest asset category is intangible assets at 82.6% of total assets.
Memphasys Ltd Competitors by Total Assets
Key competitors of Memphasys Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Memphasys Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Memphasys Ltd generates 0.05x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Memphasys Ltd is currently not profitable relative to its asset base.
Memphasys Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.14 | 0.26 | 2.64 |
| Quick Ratio | 0.10 | 0.22 | 2.51 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$-5.30 Million | AU$ -3.39 Million | AU$ 1.31 Million |
Memphasys Ltd - Advanced Valuation Insights
This section examines the relationship between Memphasys Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.25 |
| Latest Market Cap to Assets Ratio | 0.58 |
| Asset Growth Rate (YoY) | -11.3% |
| Total Assets | AU$11.02 Million |
| Market Capitalization | $6.40 Million USD |
Valuation Analysis
Below Book Valuation: The market values Memphasys Ltd's assets below their book value (0.58 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Memphasys Ltd's assets decreased by 11.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Memphasys Ltd (2007–2025)
The table below shows the annual total assets of Memphasys Ltd from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$11.02 Million | -11.33% |
| 2024-06-30 | AU$12.43 Million | -15.26% |
| 2023-06-30 | AU$14.67 Million | +3.87% |
| 2022-06-30 | AU$14.12 Million | -3.15% |
| 2021-06-30 | AU$14.58 Million | +29.05% |
| 2020-06-30 | AU$11.30 Million | +65.27% |
| 2019-06-30 | AU$6.84 Million | +62.11% |
| 2018-06-30 | AU$4.22 Million | -42.24% |
| 2017-06-30 | AU$7.30 Million | +1.49% |
| 2016-06-30 | AU$7.19 Million | +5.11% |
| 2015-06-30 | AU$6.84 Million | -3.63% |
| 2014-06-30 | AU$7.10 Million | -47.90% |
| 2013-06-30 | AU$13.63 Million | +52.28% |
| 2012-06-30 | AU$8.95 Million | -15.32% |
| 2011-06-30 | AU$10.57 Million | -40.33% |
| 2010-06-30 | AU$17.72 Million | +207.77% |
| 2009-06-30 | AU$5.76 Million | +13.86% |
| 2008-06-30 | AU$5.06 Million | +13.28% |
| 2007-06-30 | AU$4.46 Million | -- |